| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRSS23 |
| Uniprot No | O95084 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-383aa |
| 氨基酸序列 | QVSPYSAPWKPTWPAYRLPVVLPQSTLNLAKPDFGAEAKLEVSSSCGPQCHKGTPLPTYEEAKQYLSYETLYANGSRTETQVGIYILSSSGDGAQHRDSGSSGKSRRKRQIYGYDSRFSIFGKDFLLNYPFSTSVKLSTGCTGTLVAEKHVLTAAHCIHDGKTYVKGTQKLRVGFLKPKFKDGGRGANDSTSAMPEQMKFQWIRVKRTHVPKGWIKGNANDIGMDYDYALLELKKPHKRKFMKIGVSPPAKQLPGGRIHFSGYDNDRPGNLVYRFCDVKDETYDLLYQQCDAQPGASGSGVYVRMWKRQQQKWERKIIGIFSGHQWVDMNGSPQDFNVAVRITPLKYAQICYWIKGNYLDCREG |
| 预测分子量 | 45.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PRSS23重组蛋白的关键文献摘要：
1. **文献名称**: PRSS23 promotes gastric cancer metastasis via activation of NF-κB signaling
**作者**: Zhang Y et al.
**摘要**: 本研究通过重组PRSS23蛋白实验，发现其通过激活NF-κB信号通路增强胃癌细胞侵袭转移能力，并证明其与患者预后不良相关(Cancer Res, 2018)。
2. **文献名称**: Structural characterization of recombinant PRSS23 protease
**作者**: Koshikawa N et al.
**摘要**: 首次报道重组人PRSS23蛋白的晶体结构，揭示其底物结合位点及催化机制，为开发靶向抑制剂提供结构基础(J Biol Chem, 2016)。
3. **文献名称**: PRSS23 modulates VEGF signaling through cleavage of extracellular matrix proteins
**作者**: Li H et al.
**摘要**: 利用重组PRSS23证实其通过降解纤连蛋白释放VEGF，促进血管生成，在结肠癌小鼠模型中验证其促肿瘤作用(Oncogene, 2020)。
注：以上文献信息为示例性内容，实际引用需核对具体文献来源及发表年份。建议通过PubMed或Web of Science以"PRSS23 AND recombinant"为关键词获取最新研究。
PRSS23. also known as transmembrane protease serine 23 or polyserase-2. is a member of the serine protease family characterized by a conserved catalytic triad (His, Asp, Ser) essential for enzymatic activity. Initially identified in 2001. it is encoded by the *PRSS23* gene located on human chromosome 11q14.3. Unlike typical serine proteases, PRSS23 contains a transmembrane domain near its C-terminus, anchoring it to cellular membranes, and undergoes post-translational modifications like glycosylation for functional maturation.
This protease plays roles in extracellular matrix (ECM) remodeling, cell signaling, and tissue homeostasis. It cleaves substrates such as procollagen, suggesting involvement in skin aging, wound healing, and fibrosis. PRSS23 is upregulated in pathological conditions, including cancers (e.g., breast, ovarian, and hepatocellular carcinoma), where it promotes tumor progression by activating pro-metastatic pathways like epithelial-mesenchymal transition (EMT). It also contributes to inflammatory diseases by modulating immune responses.
Recombinant PRSS23 protein is produced using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His-tag) for purification. Its recombinant form enables biochemical studies, inhibitor screening, and structural analysis to elucidate substrate specificity and regulatory mechanisms. Challenges in production include maintaining proper folding and post-translational modifications critical for activity. Current research focuses on its therapeutic potential as a biomarker or target for cancers and fibrotic disorders, though its complex biology warrants further exploration.
×
